Investor Centre

Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector. Sue is also appointed to several academic and government advisory committees including CSIRO Health and Biosecurity Advisory Committee, Prime Ministers Digital Expert Advisory Committee, DMTC Medical Countermeasures and various COVID19 taskforces.

Sue commenced the role as Chair of Oventus Medical Ltd (ASX:OVN) in November 2020 along with Chair of Oventus’ Remuneration Committee. She is also Chair of MTPConnect (Medical Technology and Pharmaceuticals Industry Innovation Growth Centre Ltd MTPII-GC Ltd), Chair of Anatara Lifesciences Ltd (ASX:ANR), Chair of Tali Digital Ltd (ASX:TD1), Non-Executive Director of Palla Pharma Ltd (ASX:PAL) and Non-Executive Director of veski. Her broad commercial experience is underpinned by her qualifications including a Bachelor of Pharmacy (University of Queensland), Masters of Marketing at Melbourne University (Melbourne Business School) and a Masters of Law degree (Deakin University). Sue is also Fellow and Chair Health Forum ATSE, Fellow ACPP and Fellow/Graduate of AICD.

Based in Oventus’ US office in Irvine, California, John Cox has over 30 years’ experience in the MedTech sector, including directly relevant experience in Sleep Apnea and therapeutic technology marketing and operations. John joined Oventus in June 2021 as President and COO, before transitioning to the role of CEO in February, 2022. Prior to this, John was President and CEO of Somnera, Inc, where he developed a cloud-connected alternative to CPAP and built out direct to consumer, customer engagement and channel partner programs.

In his earlier roles, John served in executive positions at market-leading companies in medical technology and therapeutics, including USGI Medical, B.Braun Aesculap, Applied Medical and Covidien/US Surgical. John holds a BA and MBA with Honors from the University of Virginia and is the named inventor or co-inventor on over 30 U.S. patents.

Chris is the founder of the Company and inventor of the O2Vent design concept. Chris oversaw the launch of the O2Vent to patients and through clinicians and led the management team in the initial roll-out of the Oventus Sleep Treatment Platform across Australia, the United States and Canada. In his role as CSO, Dr Hart heads Oventus’ scientific “first line therapy” initiative, leading scientific and clinical research projects designed to position the O2Vent Optima technology as the first choice for patients and clinicians for the treatment of Obstructive Sleep Apnea.

Chris is also heavily involved with training and presenting to the dental and sleep sector. Chris graduated from the University of Queensland in 1998 with a Bachelor of Dental Science with Honours and a Bachelor of Science in Biochemistry. He has studied at Cambridge University where he graduated with a Master of Philosophy in Biomedical Science in 1999. Prior to establishing Oventus, Chris owned and managed a multi-site national dental practice, training institute and management consultancy which he sold to private equity investors.

Mel has over 35 years’ experience founding and building international lifescience, diagnostic and medical device companies and commercialising a wide range of Australian technology. He is responsible for numerous commercial and M&A transactions and liquidity events, including listings on the ASX. Mel has received national and state business awards including the 2005 AusBiotech Chairman’s Industry Medal and 2004 Queensland Entrepreneur of the Year. Mel has founded and developed medical device and diagnostic companies, including Pacific Diagnostics (acquired by Baxter), PanBio Ltd (acquired by Inverness Medical), and ImpediMed Ltd (ASX: IPD). Mel retired from the role of Chair for Oventus in November 2020. He moved to a Non-Executive Director role and now chairs the Oventus Audit & Risk Committee.

Based in Southern California, Paul Molloy has considerable global and US medical device industry expertise, with twenty-five years’ experience leading a range of public, private and venture capital funded healthcare companies. He is currently President and CEO of ClearFlow Inc., a US-based medical device company. Before joining ClearFlow, Paul was CEO at VasoNova Inc.- a Silicon Valley-based, venture funded vascular navigation company which was acquired by Teleflex Inc. (NYSE, TFX), in January 2011. Following the acquisition, he was appointed President of Teleflex’ largest division – ARROW Vascular – having full P&L responsibilities for direct sales, US and overseas manufacturing plants, R&D and strategic planning. Mr Molloy has also exited a number of leading US medical devices firms, including publicly traded cerebral oxygenation monitoring firm, CAS Medical Inc., and Revolutionary Medical Devices. He also serves on the Board at Augustine Medical a privately held market leader in medical arena temperature management and Inscope Inc., a venture capital-funded critical care firm. Paul started his career as a CRNA (Certified Registered Nurse Anesthetist). He holds an MBA (Chicago Booth School of Business) with a focus on finance and economics.

Based in Menlo Park, CA, Jake Nunn has more than 25 years’ experience in the life science industry as an investor, independent director, research analyst and investment banker. Jake is currently a venture advisor at New Enterprise Associates (NEA), where he was a partner from 2006 to 2018. Jake is a Director of Addex Therapeutics (SIX,Nasdaq: ADXN), Qool Therapeutics, Inc., Regulus Therapeutics (Nasdaq: RGLS) and Trevena, Inc. (Nasdaq: TRVN). He was a previous Director of several companies in the pharmaceutical sector including Dermira Inc. (acquired by Eli Lilly) and Hyperion Therapeutics (acquired by Horizon Pharma plc), and a board observer at Vertiflex, Inc. (acquired by Boston Scientific).  Prior to NEA, Jake was a Partner specializing in life sciences investing at MPM Capital. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons.  Jake received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Jake holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and recently completed the Stanford GSB Directors’ Consortium executive education program.

Steve has extensive experience in mergers and acquisitions, business valuations, accountancy and income tax compliance services, as well as board corporate governance. Steve provides company secretary services for a number of biotech and software companies. Steve is also a member of the Institute of Chartered Accountants in Australia, and the Australian Institute of Company Directors.

Based in California, Mike Sisk brings more than 25 years’ experience in finance and accounting. His broad experience ranges from smaller community banks to $8 billion publicly traded financial institutions. Prior to joining Oventus, Mike was Finance Executive with Signature Analytics, providing complete accounting and CFO services to companies with revenue ranging from start-ups with no revenue, to companies with USD$100 million in revenue. Through this role, he provided support to a number of growing MedTech businesses.

Mike’s earlier roles include Executive Vice President and CFO for Commercial Bank of California and Senior VP and Chief Accounting Officer for Axos Bank. Mike holds a BA in Accounting and Psychology from California State University, San Bernardino and an MBA in Finance from the University of La Verne.